Research
Nucleotide excision repair deficiency identified by mutational signatures is associated with cisplatin response in triple-negative breast cancer
Nature ·
The Brief
- A study links nucleotide excision repair deficiency, identified through mutational signatures, to cisplatin response in triple-negative breast cancer.
- The reported association concerns how these tumours respond to cisplatin treatment.
Why it matters
Mutational signatures that reveal repair deficiency could help identify which triple-negative breast cancer patients are more likely to respond to cisplatin, which may inform treatment selection.
Who’s affected
- oncologists and breast cancer researchers
- patients with triple-negative breast cancer
- #breast cancer
- #cisplatin
- #dna repair
- #mutational signatures
- #precision oncology